ClinicalTrials.gg
RecruitingNCT06345053Updated Apr 3, 2024

Presence of PTSD and Emotion Dysregulation Among Inpatients With Substance Use Disorder

An interventional study of Narrative Exposure Therapy in Post Traumatic Stress Disorder, Substance Use Disorders and Emotion Regulation, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 2 years 10 months after the study started (first participant enrolled May 2021, registered Mar 2024).
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Stress Disorders, Post-Traumatic with a site in Norway — 9 open to participants now, 12 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Norway.

Planned enrollment
12th of 27
100 · median 96
Started
2021
with 2 others
No phase
24 of 39
8 open now
Primary completion
2024-10
later than 1 of 11 live
Registered
32nd of 39
by date
Lead sponsor
3 of 39
Norwegian University of Science and Technology

Among the 39 studies in Stress Disorders, Post-Traumatic with a site in Norway, this one is the 12th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2021, is one of 24 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 32nd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

9 of the 39 studies in Stress Disorders, Post-Traumatic with a site in Norway are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Stress Disorders, Post-Traumatic with a site in Norway, or all of them as a file.
02

Study summary

There are high rates of co-occurring posttraumatic stress disorder (PTSD) among patients receiving treatment for substance use disorder (SUD). PTSD and SUD should be treated simultaneously, but adults in SUD treatment are often not assessed for PTSD nor offered PTSD-based interventions. One of the reasons for reluctance in offering trauma focused treatment is increased risk of drop out. PTSD and related emotion dysregulation are related to elevated psychological burden, higher dropout rates and increased risk of relapse. this is a feasibility study, where the plan is to integrate a combination of Dialectical Behaviour Therapy for Substance Use Disorder (DBT-SUD skills) a therapy targeting difficulties in emotion regulation and Narrative Exposure Therapy (NET) a trauma focused therapy, for patients with co-occurring PTSD symptoms into standard SUD treatment . The plan is to assess its potential benefits by assessing whether adding this combination to standard SUD treatment is relevant, feasible, acceptable, and safe. Treatment outcomes are 1) Prevalence of PTSD, suicidal behaviour, and self-harm, as well as the severity of difficulties in emotion regulation and emotional avoidance among patients (N approx. = 100) in inpatient treatment for SUD. 2) Change post-treatment and at 3 and 12 months follow up, from baseline in PTSD symptom severity, depressive symptoms, emotion regulation, emotion avoidance, and experience of shame. 3) Rates of dropout and relapse compared to previous rates.

This project can increase knowledge about psychological mechanisms in co-occurring PTSD and SUD and improve the quality of treatment for this vulnerable patient population.

03

Conditions studied

  • Post Traumatic Stress Disorder
  • Substance Use Disorders
  • Emotion Regulation
  • Suicide
  • Self-harm

Keywords

  • Dialectical Behaviour Therapy
  • Narrative Exposure Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • General inclusion criteria for the study:

    1. Fit general inclusion criteria for the in-patient program.
    2. Speak Scandinavian (Norwegian, Danish and/or Swedish).
    3. Be willing to sign a consent.

Inclusion criteria for NET intervention:

  1. Experience of an aversive event that fits criteria A for PTSD as defined by -V (DSM-V) (American Psychiatric Association [APA], 2013).
  2. Experience symptoms of PTSD as defined by the DSM-V (APA, 2013), or subthreshold PTSD (Grubaugh et al., 2005), or experience symptoms as evaluated by a NET therapist.

    1. Subthreshold PTSD is defined as having experienced a traumatic event (Criteria A), meeting Criteria B (re-experiencing symptoms), Criteria E (one-month symptom duration), and Criteria F (significant distress or functioning impairment) and either Criteria C (avoidance or numbing symptoms) or Criteria D (hyper arousal symptoms).

Inclusion criteria for DBT intervention:

  1. Experience difficulties in emotion regulation evaluated by an assigned DBT therapist.
  2. Manage to commit to participating in the DBT- skills training.

Exclusion Criteria:

  • General exclusion criteria for the study:

    1. Have a clinically significant low cognitive- and/or linguistic functioning that hinders the patient in understanding and answering the questions on the self-rapport instruments.

Exclusion criteria for NET and/or DBT-SUD skills

  1. Being actively psychotic.
  2. Have a (BMI) under 17.
  3. Severe dissociation.
  4. An ongoing traumatic contact with the perpetrator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Trauma fit inclusion / accept participation in DBT-SUD skills NET

    All patients with relevant will be offered to participate in DBT-SUD skills training and or NET.

    Behavioral: Narrative Exposure Therapy

Interventions

  • BehavioralNarrative Exposure Therapy

    The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.

    Also known as: Dialectical Behaviour Therapy

06

What researchers measure

Primary outcomes

  1. The intervention is relevant - prevalence of PTSD /SUP PTSD.

    The prevalence of PTSD/SUB-PTSD is measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) a 30-item structured interview used to make current (past month) diagnosis of PTSD, make lifetime diagnosis of PTSD, and assess PTSD symptoms over the past week (Weathers et al., 2018). Frequency and intensity rating is summed to create an overall PTSD symptom severity score and is used to generate a categorical diagnosis (PTSD/Sub-PTSD vs non-PTSD). In this project, we will both use the categorical diagnosis to compare those with and without PTSD/Sub-PTSD, as using the overall PTSD symptom severity scores (Weathers et al., 2018).

    Time frame: One time assessment 5 weeks after admission to treatment

  2. The intervention is relevant - prevalence of traumatic experiences.

    The prevalence of traumatic experiences also as offenders is measured with Stressful Life Events Screening Questionnaire-Revised (SLESQ) is self-report instrument designed to map and assess 15 potentially traumatic experiences (Goodman et al., 1998). The score is used to identify experiences of potential traumatic events. For this project, items asking about experiences where the participant caused potentially traumatic experiences to others are added. This is to identify violent offenders.

    Time frame: One time assessment 5 weeks after admission to treatment

  3. The intervention is relevant - The severitiy of difficulties in emotion regulation.

    The severity of difficulties in emotion regulation will be measured with Difficulties in Emotion Regulation Scale (DERS) is a self-report instrument consisting of 36 items meant to measure difficulties in emotion regulation, higher scores ranging from 36- 144 indicate more significant difficulties in emotion regulation (Gratz \& Roemer, 2004). We will use the cut score of 97 to identify severe difficulties in emotion regulation (Bemmouna et. Al 2022; Neacsiu et. al., 2014).

    Time frame: One time assessment 5 weeks after admission to treatment

  4. The intervention is feasible, accepted and safe - The dropout rate from treatment.

    The dropout rate from the standard treatment, DBT- SUD skills and NET. Dropout is registered, and dichotomous variables are created (yes/no). In case of dropout, time from admission to dropout is registered.

    Time frame: From treatment start to compleation up to 9 months.

  5. The intervention is safe - Suicide behaviour while in treatment.

    Prevalance of suicide behavior before treatment and while in treatment is registrert with the Columbia-suicide severity rating scale (C-SSRS) a suicidal ideation and behaviour-rating interview created to evaluate suicide risk. The interview consists of 10 categories with binary responses (yes/no) to indicate a presence or absence of the behaviour. The outcome of the C-SSRS is a numerical score obtained from the categories (Posner et.al. 2011). The participants Answer the interview 5 weeks from treatment start and at treatment compleation.

    Time frame: From treatment start to compleation up to 9 months.

  6. The intervention is safe - Self-harm behaviour while in treatment.

    Prevelance of Self-harm behaviour before tratment and while in treatment is registrert with The Deliberate Self-Harm Inventory (DSHI). DSHI is a 17 -item behaviourally based, self-report instrument to assess deliberate self-harm (Gratz, 2001). In this project we create a continuous variable on frequency of self-harm behaviour and a dichotomous variable on presence of self-harm (Yes/No). e of the C-SSRS is a numerical score obtained from the categories (Posner et.al. 2011). The participants answer the DSHI at 5 weeks from treatment start and at treatment compleation.

    Time frame: From treatment start to compleation up to 9 months.

  7. The intervention is accepted - participation in DBT-SUD skills sessions.

    The percentage of DBT-SUD skills sessions participated in, as well as the percentage completion of homework.

    Time frame: From treatment start to compleation up to 9 months.

  8. The intervention is feasible and accepted - Objective experience of treatment.

    A self-rapport questionnaire is designed to evaluate the experience of the treatment. Rating on a 5 Likert scale how different elements of the treatment are experienced on a 5-point scale. There are also open-ended questions about what in the treatment is most useful and what was the least helpful (see attachment 1-2 in protocol)

    Time frame: From treatment start to treatment compleation up to 9 months.

Secondary outcomes

  1. The potential benefits of the intervention - Change in PTSD symptoms from base line to 3-and 12 month follow up.

    Evaluate the change post-treatment and at 3 and 12 months follow up, from baseline in PTSD symptom severity, measured with PTSD Checklist for DSM-5 (PCL-5), a self-report instrument developed for quick screening of PTSD symptoms. Sum scores range from 0-80, with a score over 33 indicating the presence of PTSD (Weathers et al., 2013).

    Time frame: From 5 weeks after admission to treatment to 12-month follow upp after treatment completion. Up to 21 months.

  2. The potential benefits of the intervention - Change in Difficulties in emotion regulation from baseline to 3- to 12- month follow up.

    difficulties in emotion regulation measured with Difficulties in Emotion Regulation Scale (DERS) a self-report instrument consisting of 36 items meant to measure difficulties in emotion regulation, higher scores ranging from 36- 144 indicate more significant difficulties in emotion regulation (Gratz \& Roemer, 2004). We will use the cut score of 97 to identify severe difficulties in emotion regulation (Bemmouna et. Al 2022; Neacsiu et. al., 2014).

    Time frame: From 5 weeks after admission to treatment to 12-month follow upp after treatment completion. Up to 21 months.

  3. The potential benefits of the intervention - Relapse to alcohol abuse at 3- and 12-months follow up.

    Alcohol Use Disorders Identification Test (AUDIT) is a 10-item screening instrument to assess severity of alcohol consumption, drinking behaviours, and alcohol-related problems. Audit scores range from 0-40 with higher scores indicating greater problems related to alcohol consumptions (Aasland, Amundsen, Bovi, Fauske \& Mørland, 1990). In this project, the consumption score (question 1) with cut-of score 3 and over (drinking alcohol 2 -3 times a week) is coded into a dichotomous variable of current alcohol use (yes/no) and sum score used to assess severity of alcohol related problems. At 3 months or 12 months evaluation a cut-off score 3 and over on question 1 is registered as relapse.

    Time frame: From treatment completion to 3- and 12 month follow up - up to 12 months.

  4. The potential benefits of the intervention - Relapse to substance abuse at 3- and 12-month follow up.

    Realalse to substance abuse is evaluated with the Drug Use Disorder Identification Test (DUDIT), a nine item self-report instrument developed for identification of individuals with drug-related problems. DUDIT scores range from 0-44 with higher scores indicating more drug use and drug related problems (Berman, Palmstierna, Källmén, \& Bergman, 2007). In this project, the substance use frequency score (question 1) is used to identify current substance use with cut-off score score 3 and over (using substances 2-3 times a week) will be coded into a dichotomous variable (yes/no). The sum score is used to assess severity of substance related problems. At 3 months or 12 months evaluation a cut-off score 3 and over on question 1 is registered as relapse.

    Time frame: From treatment completion to 3- and 12 month follow up - up to 12 months.

07

Study locations

1 of 1 sites recruiting
  • Molde Treatment Center, Møre and Romsdal Hospital Trust
    Molde, Møre And Romsdal 6410, Norway
    Recruiting
08

References and documents

Publications

  • Aasland OG, Amundsen A, Bovim G, Fauske S, Morland J. [Identification of patients at risk of alcohol related damage]. Tidsskr Nor Laegeforen. 1990 May 10;110(12):1523-7. Norwegian. PubMed 2339403 ↗
  • Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas. 2013;25(2):191-2. doi: 10.1590/s2317-17822013000200017. No abstract available. PubMed 24413388 ↗
  • Bemmouna D, Coutelle R, Weibel S, Weiner L. Feasibility, Acceptability and Preliminary Efficacy of Dialectical Behavior Therapy for Autistic Adults without Intellectual Disability: A Mixed Methods Study. J Autism Dev Disord. 2022 Oct;52(10):4337-4354. doi: 10.1007/s10803-021-05317-w. Epub 2021 Oct 9. PubMed 34626285 ↗
  • Berman AH, Palmstierna T, Kallmen H, Bergman H. The self-report Drug Use Disorders Identification Test: Extended (DUDIT-E): reliability, validity, and motivational index. J Subst Abuse Treat. 2007 Jun;32(4):357-69. doi: 10.1016/j.jsat.2006.10.001. Epub 2006 Dec 11. PubMed 17481459 ↗
  • Brady, K. T., Back, S. E., & Coffey, S. F. (2004). Substance abuse and posttraumatic stress disorder. Current directions in psychological science, 13(5), 206-209.
  • Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014 Jun;13(2):153-60. doi: 10.1002/wps.20128. PubMed 24890068 ↗
  • Elbert, T., Hermenau, K., Hecker, T., Weierstall, R., & Schauer, M. (2012). FORNET: Behandlung von traumatisierten und nicht-traumatisierten Gewalttätern mittels Narrativer Expositionstherapie.
  • Elbert, T., Schauer, M., & Neuner, F. (2015). Narrative exposure therapy (NET): Reorganizing memories of traumatic stress, fear, and violence. In Evidence based treatments for trauma-related psychological disorders (pp. 229-253). Springer, Cham.
  • Espie CA, Farias Machado P, Carl JR, Kyle SD, Cape J, Siriwardena AN, Luik AI. The Sleep Condition Indicator: reference values derived from a sample of 200 000 adults. J Sleep Res. 2018 Jun;27(3):e12643. doi: 10.1111/jsr.12643. Epub 2017 Nov 29. PubMed 29193493 ↗
  • Goodman LA, Corcoran C, Turner K, Yuan N, Green BL. Assessing traumatic event exposure: general issues and preliminary findings for the Stressful Life Events Screening Questionnaire. J Trauma Stress. 1998 Jul;11(3):521-42. doi: 10.1023/A:1024456713321. PubMed 9690191 ↗
  • Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB. PubMed 12900694 ↗
  • Gratz, K. L. (2001). Measurement of deliberate self-harm: Preliminary data on the Deliberate Self-Harm Inventory. Journal of psychopathology and behavioral assessment, 23(4), 253-263.
  • Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. Journal of psychopathology and behavioral assessment, 26(1), 41-54.
  • Grubaugh AL, Magruder KM, Waldrop AE, Elhai JD, Knapp RG, Frueh BC. Subthreshold PTSD in primary care: prevalence, psychiatric disorders, healthcare use, and functional status. J Nerv Ment Dis. 2005 Oct;193(10):658-64. doi: 10.1097/01.nmd.0000180740.02644.ab. PubMed 16208161 ↗
  • Harder DW, Cutler L, Rockart L. Assessment of shame and guilt and their relationships to psychopathology. J Pers Assess. 1992 Dec;59(3):584-604. doi: 10.1207/s15327752jpa5903_12. PubMed 1487811 ↗
  • Hogue A, Schumm JA, MacLean A, Bobek M. Couple and family therapy for substance use disorders: Evidence-based update 2010-2019. J Marital Fam Ther. 2022 Jan;48(1):178-203. doi: 10.1111/jmft.12546. Epub 2021 Aug 25. PubMed 34435387 ↗
  • Kopelowicz A, Ventura J, Liberman RP, Mintz J. Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology. 2008;41(2):77-84. doi: 10.1159/000111551. Epub 2007 Nov 23. PubMed 18033976 ↗
  • Kroenke K. & Spitzer R.L. (2002) The PHQ-9: a new depression diagnostic and severity measure. Psychiatric Annals 32:509-521.
  • Linehan, M. (2014). DBT? Skills training manual. Guilford Publications.
  • Linehan, M. M. (1993). Skills training manual for treating borderline personality disorder. Guilford Press.
  • Lopez-Castro T, Smith KZ, Nicholson RA, Armas A, Hien DA. Does a history of violent offending impact treatment response for comorbid PTSD and substance use disorders? A secondary analysis of a randomized controlled trial. J Subst Abuse Treat. 2019 Feb;97:47-58. doi: 10.1016/j.jsat.2018.11.009. Epub 2018 Nov 24. No abstract available. PubMed 30577899 ↗
  • McGovern MP, Carroll KM. Evidence-based practices for substance use disorders. Psychiatr Clin North Am. 2003 Dec;26(4):991-1010. doi: 10.1016/s0193-953x(03)00073-x. PubMed 14711132 ↗
  • Mills KL, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. Am J Psychiatry. 2006 Apr;163(4):652-8. doi: 10.1176/ajp.2006.163.4.652. PubMed 16585440 ↗
  • Najavits, L. M. (2014). Creating change: A new past-focused model for trauma and substance abuse. In P. Ouimette & J. P. Read (Eds.), Trauma and substance abuse: Causes, consequences, and treatment of comorbid disorders (2nd ed., pp. 281-303). American Psychological Association. https://doi.org/10.1037/14273-014
  • Najavits LM, Schmitz M, Gotthardt S, Weiss RD. Seeking Safety plus Exposure Therapy: an outcome study on dual diagnosis men. J Psychoactive Drugs. 2005 Dec;37(4):425-35. doi: 10.1080/02791072.2005.10399816. PubMed 16480170 ↗
  • Post-traumatic stress disorder. London: National Institute for Health and Care Excellence (NICE); 2018 Dec. Available from http://www.ncbi.nlm.nih.gov/books/NBK542453/ PubMed 31211536 ↗
  • Neacsiu AD, Eberle JW, Kramer R, Wiesmann T, Linehan MM. Dialectical behavior therapy skills for transdiagnostic emotion dysregulation: a pilot randomized controlled trial. Behav Res Ther. 2014 Aug;59:40-51. doi: 10.1016/j.brat.2014.05.005. Epub 2014 May 27. PubMed 24974307 ↗
  • Otto MW, Hearon BA, McHugh RK, Calkins AW, Pratt E, Murray HW, Safren SA, Pollack MH. A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence. J Psychoactive Drugs. 2014 Nov-Dec;46(5):402-11. doi: 10.1080/02791072.2014.960110. PubMed 25364993 ↗
  • Ouimette PC, Brown PJ, Najavits LM. Course and treatment of patients with both substance use and posttraumatic stress disorders. Addict Behav. 1998 Nov-Dec;23(6):785-95. doi: 10.1016/s0306-4603(98)00064-1. PubMed 9801716 ↗
  • Ouimette, P., Moos, R. H., & Brown, P. J. (2003). Substance use disorder-posttraumatic stress disorder comorbidity: A survey of treatments and proposed practice guidelines. In P. Ouimette & P. J. Brown (Eds.), Trauma and substance abuse: Causes, consequences, and treatment of comorbid disorders (pp. 91-110). American Psychological Association. https://doi.org/10.1037/10460-005
  • Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704. PubMed 22193671 ↗
  • Roberts NP, Roberts PA, Jones N, Bisson JI. Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder. Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2. PubMed 27040448 ↗
  • Roemer, L., Litz, B. T., Orsillo, S. M., & Wagner, A. W. (2001). A preliminary investigation of the role of strategic withholding of emotions in PTSD. Journal of Traumatic Stress, 14(1), 149-156.
  • Saraiya T, Lopez-Castro T. Ashamed and Afraid: A Scoping Review of the Role of Shame in Post-Traumatic Stress Disorder (PTSD). J Clin Med. 2016 Nov 1;5(11):94. doi: 10.3390/jcm5110094. PubMed 27809274 ↗
  • Sinha R. Stress and addiction: a dynamic interplay of genes, environment, and drug intake. Biol Psychiatry. 2009 Jul 15;66(2):100-1. doi: 10.1016/j.biopsych.2009.05.003. No abstract available. PubMed 19555787 ↗
  • Stenmark H, Guzey IC, Elbert T, Holen A. Gender and offender status predicting treatment success in refugees and asylum seekers with PTSD. Eur J Psychotraumatol. 2014 Jan 30;5. doi: 10.3402/ejpt.v5.20803. eCollection 2014. PubMed 24494062 ↗
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Taylor CT, Laposa JM, Alden LE. Is avoidant personality disorder more than just social avoidance? J Pers Disord. 2004 Dec;18(6):571-94. doi: 10.1521/pedi.18.6.571.54792. PubMed 15615668 ↗
  • EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9. PubMed 10109801 ↗
  • Tull MT, Gratz KL, Coffey SF, Weiss NH, McDermott MJ. Examining the interactive effect of posttraumatic stress disorder, distress tolerance, and gender on residential substance use disorder treatment retention. Psychol Addict Behav. 2013 Sep;27(3):763-73. doi: 10.1037/a0029911. Epub 2012 Sep 3. Erratum In: Psychol Addict Behav. 2013 Sep;27(3):743. PubMed 22946858 ↗
  • van de Glind G, van den Brink W, Koeter MW, Carpentier PJ, van Emmerik-van Oortmerssen K, Kaye S, Skutle A, Bu ET, Franck J, Konstenius M, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitany-Foveny M, Fatseas M, Auriacombe M, Schillinger A, Seitz A, Johnson B, Faraone SV, Ramos-Quiroga JA, Casas M, Allsop S, Carruthers S, Barta C, Schoevers RA; IASP Research Group; Levin FR. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug Alcohol Depend. 2013 Oct 1;132(3):587-96. doi: 10.1016/j.drugalcdep.2013.04.010. Epub 2013 May 6. PubMed 23660242 ↗
  • Van IJzendoorn, M. H., & Schuengel, C. (1996). The measurement of dissociation in normal and clinical populations: Meta-analytic validation of the Dissociative Experiences Scale (DES). Clinical Psychology Review, 16(5), 365-382.
  • Vanderplasschen W, Vandevelde S, Broekaert E., (2014). Therapeutic communities for treating addictions in Europe. Evidence, current practices and future challenges. Luxembourg: Publications Office of the European Union.
  • Vigfusdottir, J., Hoidal, R., Breivik, E., Jonsbu, E., Dale, K. Y. & Mork, E. (2023). The Norwegian version of the Personal Feelings Questionnaire-2: The translation, clinical utility, and psychometric properties. Manuscript submitted for publication.
  • Vigfusdottir, J., Dale, K. Y., Gratz, K. L., Klonsky, E. D., Jonsbu, E., & Høidal, R. (2020). The psychometric properties and clinical utility of the Norwegian versions of the deliberate self-harm inventory and the inventory of statements about self-injury. Current Psychology, 1-11.
  • Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. doi: 10.1037/pas0000486. Epub 2017 May 11. PubMed 28493729 ↗
  • Weathers, F. W., Litz, B. T., Keane, T. M., Palmieri, P. A., Marx, B. P., & Schnurr, P. P. (2013). The ptsd checklist for dsm-5 (pcl-5). Scale available from the National Center for PTSD at www. ptsd. va. gov, 10.
  • Westphal, M., Aldao, A., & Jackson, C. (2017). Emotion dysregulation in comorbid posttraumatic stress disorder and substance use disorders: A narrative review. Military Psychology, 29(3), 216-233.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Oct 2024, 41 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 41 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Apr 3, 2024
StartActual
May 1, 2021
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 1, 2025
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345053
Collaborators
Møre og Romsdal Hospital Trust, Oslo University Hospital
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
May 1, 2021
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Apr 3, 2024

Study contacts

Johanna Vigfusdottir
Contact
johannavigfusd@gmail.com
+4746746154
Edvard Breivik
Contact
+4793032613
Egil Jonsbu
study director · Norwegian University of Science and Technology
Johanna Vigfusdottir
principal investigator · Norwegian University of Science and Technology
Edvard Breivik
principal investigator · Norwegian University of Science and Technology
Erlend Mork
study chair · Oslo University Hospital
Lars Lien
study chair · National Competence Center for Co-Occurring Addictive and Psychiatric Disorders
Håkon Stenmark
study chair · Regional Center for Violence and Traumatic Stress and St. Olavs Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion